LRRC22 Activators
LRRC22 Activators encompass a range of chemical compounds that influence various biochemical pathways, leading to an enhancement of the functional activity of LRRC22. Forskolin is notable for its role in activating adenylate cyclase, which catalyzes the conversion of ATP to cAMP, a secondary messenger that activates protein kinase A (PKA). PKA can phosphorylate a variety of proteins, potentially including those in the vicinity of or regulating LRRC22, thereby enhancing its activity. Similarly, the cAMP analog 8-Bromo-cAMP serves to activate PKA, further potentiating the potential phosphorylation events that could amplify LRRC22's role within its signaling network. The polyphenolic compound Epigallocatechin gallate (EGCG) contributes to the activation of LRRC22 by inhibiting protein kinases that may otherwise suppress LRRC22 pathways, while the sphingolipid metabolite Sphingosine-1-phosphate (S1P) operates through its receptors to initiate signaling cascades that could engage LRRC22's function.
The role of intracellular calcium in the regulation of LRRC22 is highlighted by the use of ionophores such as A23187 (Calcimycin) and Ionomycin, which increase cytosolic calcium concentrations, potentially activatingcalcium-dependent kinases and phosphatases that can modulate LRRC22 activity. Additionally, Phorbol 12-myristate 13-acetate (PMA) acts as a potent activator of protein kinase C (PKC), which can phosphorylate substrates or alter signaling pathways to indirectly enhance LRRC22's function. The strategic inhibition of key signaling nodes by compounds such as U0126, LY294002, SB203580, and PD98059 may attenuate competitive pathways like MAPK/ERK and PI3K/AKT, thus potentially facilitating the enhancement of alternative pathways that support LRRC22 function. Thapsigargin's role in increasing cytosolic calcium by inhibiting the SERCA pump also underscores the importance of calcium signaling in the modulation of LRRC22 activity. These diverse chemical activators, through their targeted effects on distinct cellular pathways, collectively contribute to the upregulation and potentiation of LRRC22-mediated functions without necessitating direct binding or allosteric modification of the protein itself.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin activates adenylate cyclase, which increases cAMP levels within cells. Elevated cAMP levels lead to the activation of protein kinase A (PKA), which can phosphorylate various targets, potentially including those that interact with or regulate LRRC22, thus enhancing its functional activity. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $42.00 $72.00 $124.00 $238.00 $520.00 $1234.00 | 11 | |
EGCG is a known inhibitor of several protein kinases. By inhibiting competitive signaling pathways, it may enhance LRRC22 pathways by reducing the phosphorylation of proteins that negatively regulate LRRC22 function. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $162.00 $316.00 $559.00 $889.00 $1693.00 | 7 | |
S1P binds to its specific G protein-coupled receptors, which can initiate signaling cascades that may mobilize secondary messengers involved in LRRC22 activation or enhance its downstream signaling processes. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $54.00 $128.00 $199.00 $311.00 | 23 | |
A23187 acts as a calcium ionophore, raising intracellular calcium levels. This increase in calcium can activate various calcium-dependent kinases and phosphatases that may indirectly enhance the functional activity of LRRC22. | ||||||
8-Bromo-cAMP | 76939-46-3 | sc-201564 sc-201564A | 10 mg 50 mg | $97.00 $224.00 | 30 | |
As a cAMP analog, 8-Bromo-cAMP activates PKA, similarly to Forskolin. PKA activation can lead to phosphorylation events that enhance the functional activity of LRRC22 by modulating its signaling partners or substrate interactions. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $76.00 $265.00 | 80 | |
Ionomycin is another calcium ionophore that raises intracellular calcium levels, indirectly promoting the activation of calcium-dependent proteins that could enhance the signaling pathways in which LRRC22 is involved. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA is an activator of protein kinase C (PKC), which could phosphorylate substrates or modulate other signaling pathways that indirectly enhance the functional activity of LRRC22. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a MEK inhibitor that blocks the MAPK/ERK pathway. By inhibiting this pathway, U0126 could shift signaling dynamics to favor pathways that positively regulate LRRC22 activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor that can alter the PI3K/AKT pathway. Inhibition of this pathway may shift cellular signaling toward mechanisms that enhance LRRC22 function. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAP kinase. Blocking p38 MAP kinase activity might result in the enhancement of alternative signaling pathways or mechanisms that positively regulate LRRC22. | ||||||